Space Flight Associated Neuro-ocular SyndromeSTOP-VIIPNCT05016414
Countermeasures for Visual Impairment in Astronauts
A study testing Lower body negative pressure in people with Space Flight Associated Neuro-ocular Syndrome, run by University of Texas Southwestern Medical Center at 1 site in United States.
Trial summary
This study is being done to prevent changes in the vision of astronauts during prolonged residence on the International Space Station or a mission to Mars. This project will provide data about the efficacy of lower body negative pressure to mimic daily upright posture by intermittently lowering central venous pressure… Read more about this study
- Who is it for?
- Ages 18 to 55 yearsHealthy volunteers can take part
- Conditions the study is for
- Space Flight Associated Neuro-ocular Syndrome
- What is being tested?
- Lower body negative pressure
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 10 participants
- Where
- 1 siteUnited States
- Study dates
- 1 Mar 2019to 1 Mar 2020
- Phase
- Interventional
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 to 55 years
- All sexes
- Healthy volunteers accepted
- Adult
Who may be able to join
- age 18-55
Who cannot join
- cardiovascular disease
- ophthalmological disease
Trial locations and contacts
1 site in 1 country.
About this study
Official title: Safe and Effective Countermeasures to Reduce Intracranial Pressure and Ameliorate Visual Impairment in Astronauts (STOP VIIP)
This study is being done to prevent changes in the vision of astronauts during prolonged residence on the International Space Station or a mission to Mars. This project will provide data about the efficacy of lower body negative pressure to mimic daily upright posture by intermittently lowering central venous pressure while in simulated microgravity (3 days of bed rest). The investigators expect that 3 days of bed rest will increase choroid thickness, and choroid area. The investigators hypothesize that nightly LBNP (-20mmHg) will prevent these changes.
Read the detailed description
The visual impairment observed in many astronauts after long duration spaceflight aboard the International Space Station is considered the most important mission-threatening medical problem identified in the last decade of the space program. Between 2012 and 2014, NASA and NSBRI have spent $3-4 million/year investigating the clinical course and underlying mechanisms of this condition, termed the Visual Impairment Intracranial Pressure Syndrome (VIIP) because of its theoretical association with elevated intracranial pressure and central venous pressure. During the previous funding cycle, the investigators for this application performed the first invasive measures of intracranial pressure during acute (head down tilt bedrest and parabolic flight) and chronic (24 hours HDT bedrest) changes in gravitational gradients simulating spaceflight in healthy humans. Novel observations made from those studies determined that 1) there is a large range of central venous pressure experienced normally during changes in posture in daily life; 2) these changes occur within seconds of postural transients from upright to supine and then are stable over time in that position; 3) with acute assumption of simulated microgravity (HDT bedrest), intracranial pressure and central venous pressure goes up slightly from the supine position, but over the next 24 hours, returns toward, and sometimes below the supine value because of spatial compensation within the brain; 4) during true microgravity (parabolic flight), the acute reduction in central venous pressure reduces cerebral outflow resistance and ICP decreases compared to the supine position, though remains above the upright position in 1G.
The current hypothesis is that the VIIP syndrome is Not due to a pathologically elevated central venous or intracranial pressure. However, because there is not the usual reduction in pressure typically seen in the upright position on earth, the incessant, low level elevation in ICP (i.e., greater than upright, but less than supine) leads to adaptive changes in the eye which ultimately result in globe flattening, choroidal folds, and visual impairment. Preliminary data suggest that the use of lower body negative pressure (LBNP) can lower ICP while in the head down position, towards the values observed upright. The investigators propose that applying LBNP during sleep in space would be a practical strategy to restore a relevant (though reversed) circadian variability in central venous pressure that would then prevent adaptive changes in the eye. The investigators propose the following hypothesis:
Hypothesis 1: Repeated administration of LBNP at night will cause a safe, sustained reduction in central venous pressure while asleep. This restoration of effective circadian variability in central venous pressure will prevent structural changes in the eye induced by microgravity. To test this hypothesis, the long-term efficacy of nightly LBNP (6-8 hrs) to simulate the upright position and prevent structural changes in the eye during four days of bedrest. Comprehensive, non-invasive state-of-the-art imaging will be used to examine the structure of the visual apparatus, using optical coherence tomography combined with invasive direct measurement of CVP.
- Being tested
- Lower body negative pressure
- Medical subject headings
- spaceflight-induced visual impairment
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Lower body negative pressureOther
lower body negative pressure at -20mmHg delivered via a custom designed sleeping sack
| Study group | Role | What they receive |
|---|---|---|
| Control | No intervention | 4 days of strict bed rest |
| Lower body negative pressure | Experimental | 4 days of strict bed rest with nightly lower body negative pressure at -20mmHg Receives: Other: Lower body negative pressure |
What is being measured
The primary outcome is the main question the study is designed to answer.
Change in choroid area
The change in choroid area measured by optical coherence tomography.
Measured: Baseline, after 3-days of bed rest
Change in choroid volume
The change in choroid volume measured by optical coherence tomography.
Measured: Baseline, after 3-days of bed rest
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted23 Aug 2021
- Study start1 Mar 2019
- Primary completion1 Mar 2020
- Study completion1 Mar 2020
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Publications (1)Papers the sponsor has linked to this study.
- Other trials for Space Flight Associated Neuro-ocular SyndromeStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Basic science
- Allocation
- Randomised
- Intervention model
- Crossover
- Masking
- Single blind
- Who is masked
- Outcomes assessor
- Enrolment
- 10 participants (actual)
Sponsor and investigators
- Lead sponsor
- University of Texas Southwestern Medical Center
- Sponsor type
- University, hospital or other
- Responsible party
- Principal investigator, Benjamin Levine, University of Texas Southwestern Medical Center
- Investigators
- Benjamin Levine, MD, Principal investigator, University of Texas Southwestern Medical Center
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT05016414
- Sponsor's protocol ID
- STU 102015-057
- Acronym
- STOP-VIIP
- Status last verified
- Aug 2021
- First submitted
- 9 Aug 2021
- Last updated
- 8 Sep 2021
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- No
Publications
Hearon CM Jr, Peters K, Dias KA, Macnamara JP, Marshall JET, Campain J, Martin D, Marshal-Goebel K, Levine BD. Assessment of venous pressure by compression sonography of the internal jugular vein during 3 days of bed rest. Exp Physiol. 2023 Dec;108(12):1560-1568. doi: 10.1113/EP091372. Epub 2023 Oct 12.
PubMed 37824038
Study at a glance
From the registry record, last updated by the sponsor on 8 Sep 2021. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Safe and Effective Countermeasures to Reduce Intracranial Pressure and Ameliorate Visual Impairment in Astronauts (STOP VIIP)
- ClinicalTrials.gov ID
- NCT05016414
- Acronym / sponsor ID
- STOP-VIIP / STU 102015-057
- Study type
- Interventional
- Recruitment status
- Completed
- Enrolment
- 10 participants (actual)
- Lead sponsor
- University of Texas Southwestern Medical CenterUniversity, hospital or other
- Study start
- 1 Mar 2019 (actual)
- Primary completion
- 1 Mar 2020 (actual)
- Study completion
- 1 Mar 2020 (actual)
- First posted
- 23 Aug 2021 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
This study is being done to prevent changes in the vision of astronauts during prolonged residence on the International Space Station or a mission to Mars. This project will provide data about the efficacy of lower body negative pressure to mimic daily upright posture by intermittently lowering central venous pressure while in simulated microgravity (3 days of bed rest). The investigators expect that 3 days of bed rest will increase choroid thickness, and choroid area. The investigators hypothesize that nightly LBNP (-20mmHg) will prevent these changes.
Detailed description
The visual impairment observed in many astronauts after long duration spaceflight aboard the International Space Station is considered the most important mission-threatening medical problem identified in the last decade of the space program. Between 2012 and 2014, NASA and NSBRI have spent $3-4 million/year investigating the clinical course and underlying mechanisms of this condition, termed the Visual Impairment Intracranial Pressure Syndrome (VIIP) because of its theoretical association with elevated intracranial pressure and central venous pressure. During the previous funding cycle, the investigators for this application performed the first invasive measures of intracranial pressure during acute (head down tilt bedrest and parabolic flight) and chronic (24 hours HDT bedrest) changes in gravitational gradients simulating spaceflight in healthy humans. Novel observations made from those studies determined that 1) there is a large range of central venous pressure experienced normally during changes in posture in daily life; 2) these changes occur within seconds of postural transients from upright to supine and then are stable over time in that position; 3) with acute assumption of simulated microgravity (HDT bedrest), intracranial pressure and central venous pressure goes up slightly from the supine position, but over the next 24 hours, returns toward, and sometimes below the supine value because of spatial compensation within the brain; 4) during true microgravity (parabolic flight), the acute reduction in central venous pressure reduces cerebral outflow resistance and ICP decreases compared to the supine position, though remains above the upright position in 1G.
The current hypothesis is that the VIIP syndrome is Not due to a pathologically elevated central venous or intracranial pressure. However, because there is not the usual reduction in pressure typically seen in the upright position on earth, the incessant, low level elevation in ICP (i.e., greater than upright, but less than supine) leads to adaptive changes in the eye which ultimately result in globe flattening, choroidal folds, and visual impairment. Preliminary data suggest that the use of lower body negative pressure (LBNP) can lower ICP while in the head down position, towards the values observed upright. The investigators propose that applying LBNP during sleep in space would be a practical strategy to restore a relevant (though reversed) circadian variability in central venous pressure that would then prevent adaptive changes in the eye. The investigators propose the following hypothesis:
Hypothesis 1: Repeated administration of LBNP at night will cause a safe, sustained reduction in central venous pressure while asleep. This restoration of effective circadian variability in central venous pressure will prevent structural changes in the eye induced by microgravity. To test this hypothesis, the long-term efficacy of nightly LBNP (6-8 hrs) to simulate the upright position and prevent structural changes in the eye during four days of bedrest. Comprehensive, non-invasive state-of-the-art imaging will be used to examine the structure of the visual apparatus, using optical coherence tomography combined with invasive direct measurement of CVP.
Study design
- Primary purpose
- Basic science
- Allocation
- Randomised
- Intervention model
- Crossover
- Masking
- Single blind (outcomes assessor)
- Number of arms
- 2
| Arm | Type | Receives |
|---|---|---|
| Control | No intervention | –4 days of strict bed rest |
| Lower body negative pressure | Experimental | Other: Lower body negative pressure4 days of strict bed rest with nightly lower body negative pressure at -20mmHg |
Who may qualify
- Ages
- 18 to 55 years
- Sex
- All
- Healthy volunteers
- Accepted
- Age groups
- Adult
Key inclusion criteria (1 listed)
- age 18-55
Key exclusion criteria (2 listed)
- cardiovascular disease
- ophthalmological disease
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Lower body negative pressurelower body negative pressure at -20mmHg delivered via a custom designed sleeping sack | Other | Lower body negative pressure |
Primary outcome
Change in choroid area
Time frame: Baseline, after 3-days of bed rest
The change in choroid area measured by optical coherence tomography.
Change in choroid volume
Time frame: Baseline, after 3-days of bed rest
The change in choroid volume measured by optical coherence tomography.
Results and safety
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 8 Sep 2021.
- Derived from this study: PubMed 37824038Hearon CM Jr, Peters K, Dias KA, Macnamara JP, Marshall JET, Campain J, Martin D, Marshal-Goebel K, Levine BD. Assessment of venous pressure by compression sonography of the internal jugular vein during 3 days of bed rest. Exp Physiol. 2023 Dec;108(12):1560-1568. doi: 10.1113/EP091372. Epub 2023 Oct 12.
- Individual participant dataSharing planned: No
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Benjamin Levine, MD principal investigator
University of Texas Southwestern Medical Center
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A study testing Lower body negative pressure in people with Space Flight Associated Neuro-ocular Syndrome, run by University of Texas Southwestern Medical Center at 1 site in United States.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 1 inclusion and 2 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 8 Sep 2021. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in United States. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Change in choroid area (time frame: Baseline, after 3-days of bed rest). The study lists 2 primary outcomes in all. It is what the study was designed to measure, not a finding.
Where can I read the original study information?
On the ClinicalTrials.gov record for NCT05016414, which also lists 1 linked publication.
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 8 Sep 2021.